Evidence map›Paper›PMID 30608440›Full record

Trial reportMedicine2019

Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.

Dachuan Cai, Chen Pan, Weihua Yu, Shuangsuo Dang, Jia Li, Shanming Wu, Nan Jiang, Maorong Wang, Zhaohua Zhang, Feng Lin and 4 more

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 5 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Observational
  8. Review
  9. Article
  10. Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
  13. Advances in treatment and prevention of hepatitis B.World journal of gastrointestinal pharmacology and therapeutics · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 1 country.

Dachuan CaiThe Second Affiliated Hospital of Chongqing Medical University, Chongqing.
Chen PanMengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou.
Weihua YuThe Eighth People's Hospital of Guangzhou.
Shuangsuo DangThe Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an.
Jia LiThe Second People's Hospital of Tianjin.
Shanming WuShanghai Public Health Clinical Center Shanghai.
Nan JiangSichuan Provincial People's Hospital, Chengdu.
Maorong WangNo.81 Hospital of PLA.
Zhaohua ZhangJinan Infectious Disease Hospital.
Feng LinHainan General Hospital, Haikou.
Shaojie XinNo.302 Hospital of PLA, Beijing.
Yongfeng YangThe Second Hospital of Nanjing, Nanjing.
Baoshen ShenThe First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Hong RenThe Second Affiliated Hospital of Chongqing Medical University, Chongqing.
Dalian Medical University · CN81th Hospital of PLA · CNFirst Affiliated Hospital of Xinxiang Medical University · CNFujian Medical University · CNGuangzhou Eighth People's Hospital · CNHainan General Hospital · CNJinan Infectious Disease Hospital · CNNanjing Second Hospital · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CNShanghai Public Health Clinical Center · CNSichuan Provincial Hospital of Traditional Chinese Medicine · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe conducted this study to compare the efficacy and safety of entecavir and tenofovir in the treatment of treatment-naïve HBV e antigen (HBeAg)-positive patients with chronic hepatitis B (CHB) for 144 weeks.

methodsA total of 320 treatment-naïve HBeAg-positive CHB patients who received randomly a single regimen of either entecavir capsule (ETV) (n = 160) or tenofovir disoproxil fumarate capsule (TDF) (n = 160) for 144 weeks were consecutively enrolled from 14 tertiary hospitals or university hospitals in China between January 2012 and December 2014.

resultsTwo groups showed no difference in baseline characteristics. After 144 weeks of treatment, HBV DNA levels were similarly suppressed in both groups (ETV vs TDF; -6.6485 vs -6.692 log10IU/mL, P = .807). At the same time, both groups showed no difference in terms of the serologic and biochemical response. Of all patients, 2 dropped out due to adverse events and 5 experienced serious adverse reactions.

conclusionBoth capsules (ETV or TDF) were equally effective in nucleos(t)ide-naive CHB patients with a comparable side-effect profile even in a long-term of 144 weeks.

Indexed as

AdultAntiviral AgentsChinaDNA, ViralFemaleGuanineHepatitis B, ChronicHepatitis B e AntigensHepatitis B virusHumansMaleTenofovirTreatment OutcomeAntiviral AgentsDNA, ViralentecavirGuanineHepatitis B e AntigensTenofovir

Identifiers

PMID30608440
PMCPMC6344155
OpenAlexW2908246798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.